COMP <GO>
NUTX vs TSLA // FORWARD P/E MULTIPLE
Nutex Health Inc. (NASDAQ) VS. Tesla, Inc. (NASDAQ) • 15-METRIC TALLY: NUTX 8
— TSLA 3
■ METRIC PARITY
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
forward-pe
17.1x
LAST: $403.30 (-0.23%) • MKT CAP: $1.59T
forward-pe
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUTX VS. TSLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUTX | TSLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.80% | 19.29% | +31.51 | NUTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 3.39% | +81.61 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.6x | 199.0x | -194.44 | NUTX | /valuation <GO> |
| Free Cash Flow Yield | 17.07% | 0.21% | +16.86 | NUTX | /fcf-yield <GO> |
| Operating Margin | 31.50% | 3.35% | +28.15 | NUTX | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 3.11% | +4.99 | NUTX | /net-margins <GO> |
| Revenue Growth (YoY) | 82.40% | 8.30% | +74.10 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.75 | 15.35 | -11.60 | TSLA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 8.72% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 56.6 | -9.92 | TSLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.89 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 17.1x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $1.59T | -$1.59T | TSLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUTX REV | TSLA REV | NUTX GROSS % | TSLA GROSS % | NUTX FCF | TSLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $875.3M | $94.83B | 50.8% | 18.0% | $245.6M | $6.22B |
| FY 2024 | $479.9M | $97.69B | 40.9% | 17.9% | $20.8M | $3.58B |
| FY 2023 | $247.6M | $96.77B | — | 18.3% | $1.3M | $4.36B |
| FY 2022 | — | $81.46B | — | 25.6% | — | $7.57B |
| FY 2021 | — | $53.82B | — | 25.3% | — | $5.01B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUTX // BETA —
TSLA // BETA 1.89